The Defense Health Agency awarded a $4.66 million project grant to the University of Colorado Denver to support research on a stem cell-based therapy for recessive dystrophic epidermolysis bullosa delivered with a spray-on skin device. The grant was awarded on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420) and will run through August 31, 2027. Through this funding, the University of Colorado Denver will conduct research to develop an innovative stem cell therapy and associated medical device for delivering the therapy to patients with recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder. The grant supports the university's work investigating potential medical solutions for wounded soldiers through advanced biomedical research initiatives.